SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No.     )*

 

 

Helius Medical Technologies, Inc.

(Name of Issuer)

Class A Common Stock, par value $0.001

(Title of Class of Securities)

42328V504

(CUSIP Number)

Dane Andreeff

140 East St. Lucia Lane

Santa Rosa Beach, FL 32459

(215) 944-6100

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

October 26, 2020

(Date of Event Which Requires Filing of this Statement)

 

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  ☐

 

 

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

 

 

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

CUSIP No. 42328V504

 

  1    

  NAME OF REPORTING PERSON:

 

  Dane Andreeff

  2  

  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP:

  (a)  ☐        (b)  ☒

 

  3  

  SEC USE ONLY:

 

  4  

  SOURCE OF FUNDS:

 

  AF

  5  

  CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e):

 

  ☐

  6  

  CITIZENSHIP OR PLACE OF ORGANIZATION:

 

  Canada

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH:

 

     7     

  SOLE VOTING POWER:

 

  98,510

     8   

  SHARED VOTING POWER:

 

  3,238,433

     9   

  SOLE DISPOSITIVE POWER:

 

  98,510

   10   

  SHARED DISPOSITIVE POWER:

 

  3,238,433

11    

  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

 

  3,336,943*

12  

  CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES:

 

  ☐

13  

  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11):

 

  6.3% (See Item 5 herein)

14  

  TYPE OF REPORTING PERSON:

 

  IN

 

*

Includes 1,420,525 shares of common stock and 347,296 shares of common stock issuable upon the exercise of warrants held by Maple Leaf Partners, L.P., 300,953 shares of common stock and 73,621 shares of common stock issuable upon the exercise of warrants held by Maple Leaf Partners I, L.P., 815,842 shares of common stock and 202,570 shares of common stock issuable upon the exercise of warrants held by Maple Leaf Discovery I, L.P., 58,945 shares of common stock and 18,681 shares of common stock issuable upon the exercise of warrants held by Maple Leaf Offshore, Ltd., 20,000 shares on common stock held directly by Mr. Andreeff and 78,510 shares of common stock issuable upon the exercise of stock options held directly by Mr. Andreeff.

 

2

  1    

  NAME OF REPORTING PERSON:

 

  Maple Leaf Capital I, LLC

  2  

  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP:

  (a)  ☐        (b)  ☒

 

  3  

  SEC USE ONLY:

 

  4  

  SOURCE OF FUNDS:

 

  AF

  5  

  CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e):

 

  ☐

  6  

  CITIZENSHIP OR PLACE OF ORGANIZATION:

 

  Delaware

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH:

 

     7     

  SOLE VOTING POWER:

 

  0

     8   

  SHARED VOTING POWER:

 

  3,238,433

     9   

  SOLE DISPOSITIVE POWER:

 

  0

   10   

  SHARED DISPOSITIVE POWER:

 

  3,238,433

11    

  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

 

  3,238,433*

12  

  CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES:

 

  ☐

13  

  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11):

 

  6.2% (See Item 5 herein)

14  

  TYPE OF REPORTING PERSON:

 

  OO

 

*

Includes 1,420,525 shares of common stock and 347,296 shares of common stock issuable upon the exercise of warrants held by Maple Leaf Partners, L.P., 300,953 shares of common stock and 73,621 shares of common stock issuable upon the exercise of warrants held by Maple Leaf Partners I, L.P., 815,842 shares of common stock and 202,570 shares of common stock issuable upon the exercise of warrants held by Maple Leaf Discovery I, L.P., and 58,945 shares of common stock and 18,681 shares of common stock issuable upon the exercise of warrants held by Maple Leaf Offshore, Ltd.

END OF COVER PAGE

 

3

The Reporting Persons named in Item 2 below are hereby jointly filing this Schedule 13D because due to certain relationships among the Reporting Persons, such Reporting Persons may be deemed to beneficially own the same securities named in Item 5 below by one of the Reporting Persons. In accordance with Rule 13d-1(k)(1)(iii) promulgated pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the Reporting Persons named in Item 2 below have executed a written agreement relating to the joint filing of this Schedule 13D, a copy of which is attached hereto as Exhibit 1.

 

Item 1.

Security and Issuer.

The securities covered by this Schedule 13D are shares of Class A common stock, par value $0.001 per share (the “Common Stock”), of Helius Medical Technologies, Inc., a Delaware corporation (the “Issuer”). The Issuer’s address is 642 Newtown Yardley Road, Suite 100, Newtown, Pennsylvania 18940.

 

Item 2.

Identity and Background.

(a) This statement is being filed on behalf of Dane Andreeff, a natural person, and Maple Leaf Capital I, LLC (“Maple Leaf Capital”, and together with Mr. Andreeff, the “Reporting Persons”).

(b) Each of the Reporting Persons has a principal business address at 140 East St. Lucia Lane, Santa Rosa Beach, FL 32459.

(c) Mr. Andreeff is the interim President and CEO of the Issuer, and the managing member of Maple Leaf Capital. Maple Leaf Capital purchases, holds and sells securities and other investment products.

(d)-(e) During the last five years, the Reporting Persons have not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding is or was subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

(f) Mr. Andreeff is a citizen of Canada. Maple Leaf Capital is a limited liability company formed under the laws of the State of Delaware.

 

Item 3.

Source and Amount of Funds or Other Consideration.

On October 21, 2020, the Issuer entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (the “Purchasers”), pursuant to which the Company, in a private placement (the “Private Placement”), agreed to issue and sell an aggregate of 6,567,868 shares (the “Shares”) of the Company’s Class A common stock, par value $0.001 per share (the “Common Stock”), and warrants to purchase an aggregate of 3,283,936 shares of Common Stock (the “Warrants”). Pursuant to the Purchase Agreement, affiliates of the Reporting Persons purchased 1,182,301 Shares and 591,149 Warrants for an aggregate purchase price of $620,000. The Private Placement closed on October 26, 2020.

As of the filing date of this Schedule 13D, the Reporting Persons were deemed to beneficially hold 3,326,740 shares of the Issuer’s common stock, which consisted of the Shares and Warrants purchased in the Private Placement. The Shares acquired in the Private Placement were purchased with working capital of Maple Leaf Partners, L.P. (“MLP”), Maple Leaf Partners I, L.P. (“MLPI”), Maple Leaf Partners Discovery I, L.P. (“MLD”), and Maple Leaf Offshore, Ltd. (“MLO”). Mr. Andreeff is the managing member of Maple Leaf Capital, the general partner of each of MLP, MLPI and MLD. Mr. Andreeff is the president of the managing member of Andreeff Equity Advisors, LLC, the investment manager of MLO.

The Securities Purchase Agreement is filed as Exhibit 2 hereto and incorporated herein by reference.

 

Item 4.

Purpose of Transaction.

Item 3 of this Schedule 13D is incorporated herein by reference.

 

4

As of the date of this Schedule 13D, none of the Reporting Persons have any plans or proposals which relate to or would result in any of the following actions, except as disclosed herein and except that the Reporting Persons or their affiliates may, from time to time or at any time, subject to market and general economic conditions, the requirements of federal or state securities laws and other factors, purchase additional shares of Common Stock in the open market, in privately negotiated transactions or otherwise, or sell at any time all or a portion of the shares of Common Stock now owned or hereafter acquired by them to one or more purchasers:

 

  •  

the acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer;

 

  •  

an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries;

 

  •  

a sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries;

 

  •  

any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board;

 

  •  

any material change in the present capitalization or dividend policy of the Issuer;

 

  •  

any other material change in the Issuer’s business or corporate structure;

 

  •  

changes in the Issuer’s charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person;

 

  •  

causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association;

 

  •  

a class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Act; or

 

  •  

any action similar to any of those enumerated above.

As interim President and Chief Executive Officer and a member of the Issuer’s Board of Directors, Mr. Andreeff may discuss items of mutual interest with the Issuer, which could include any of the items listed above.

 

Item 5.

Interest in Securities of the Issuer.

(a) – (b)

 

                  (b)
Number of Shares as to which the person has: 		 

Name

   (a)
Amount
Beneficially
Owned 		     (a)
Percent
of Class* 		    Sole Power to
Vote or to
Direct the
Vote 		     Shared
Power to
Vote or to
Direct the
Vote 		     Sole Power to
Dispose or to
Direct the
Disposition 		     Shared Power to
Dispose or to
Direct the
Disposition 		 

Dane Andreeff(1)

     3,336,943        6.3 %      98,510        3,238,433        98,510        3,238,433  

Maple Leaf Capital I, LLC(2)

     3,238,433        6.2 %      0        3,238,433        0        3,238,433  

 

*

Based on 45,114,506 shares of Common Stock outstanding as of August 7, 2020 as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on August 12, 2020, plus 6,567,868 shares of Common Stock issued upon the closing of the Private Placement.

(1)

Amounts listed include 1,420,525 shares of common stock and 347,296 shares of common stock issuable upon the exercise of warrants held by MLP, 300,953 shares of common stock and 73,621 shares of common stock issuable upon the exercise of warrants held by MLPI, 815,842 shares of common stock and 202,570 shares of common stock issuable upon the exercise of warrants held by MLD, 58,945 shares of common stock and 18,681 shares of common stock issuable upon the exercise of warrants held by MLO, 20,000 shares on common stock held directly by Mr. Andreeff and 78,510 shares of common stock issuable upon the exercise of stock options held directly by Mr. Andreeff. Mr. Andreeff is the managing member of Maple Leaf Capital, the general partner of each of MLP, MLPI, and MLD. Mr. Andreeff is the president of the managing member of Andreeff Equity Advisors, LLC, the investment manager of MLO. Mr. Andreeff and Maple

 

5

  Leaf Capital may be deemed to have voting and dispositive power with respect to the shares of Common Stock held by MLP, MLPI, MLD, and MLO.
(2)

Amounts listed include 1,420,525 shares of common stock and 347,296 shares of common stock issuable upon the exercise of warrants held by MLP, 300,953 shares of common stock and 73,621 shares of common stock issuable upon the exercise of warrants held by MLPI, 815,842 shares of common stock and 202,570 shares of common stock issuable upon the exercise of warrants held by MLD, and 58,945 shares of common stock and 18,681 shares of common stock issuable upon the exercise of warrants held by MLO. Maple Leaf Capital is the general partner of each of MLP, MLPI, and MLD, and may be deemed to have voting and dispositive power with respect to the shares of Common Stock held by MLP, MLPI, and MLD.

(c) Except for the transactions described in Items 3, 4, or 5 of this Schedule 13D, during the last sixty days there were no transactions with respect to the Common Stock effected by the Reporting Persons.

(d) Except as set forth in this Item 5, no person other than each respective record owner of securities referred to herein is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities discussed herein.

(e) Not applicable.

 

Item 6.

Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

Except as described above, there are no other contracts, arrangements, understandings or relationships (legal or otherwise) including, but not limited to, transfer or voting of any of the securities, finder’s fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies, among the Reporting Persons and any other person, with respect to any securities of the Issuer, including any securities pledged or otherwise subject to a contingency the occurrence of which would give another person voting power or investment power over such securities.

 

Item 7.

Material to be Filed as Exhibits.

 

Exhibit 1    Joint Filing Agreement
Exhibit 2    Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by the Issuer on 10-26-2020, File No. 001-38445)

 

6

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: November 5, 2020

 

DANE ANDREEFF, INDIVIDUALLY
/s/ Dane Andreeff
MAPLE LEAF CAPITAL I, LLC
/s/ Dane Andreeff
Dane Andreeff, Managing Member

 

7

EXHIBIT 1

JOINT FILING AGREEMENT

The undersigned hereby agree that the statement on Schedule 13D with respect to the Common Stock of Helius Medical Technologies, Inc. dated November 5, 2020, and any amendments thereto signed by each of the undersigned, shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.

Dated: November 5, 2020

 

DANE ANDREEFF, INDIVIDUALLY
/s/ Dane Andreeff
MAPLE LEAF CAPITAL I, LLC
/s/ Dane Andreeff
Dane Andreeff, Managing Member

 

8